Compound ID | 797
acpP PMO
Class: Phosphorodiamidate morpholino oligomer (PMO)
| Spectrum of activity: | Gram-positive |
| Details of activity: | Blocks expression of the acpP gene through an antisense mechanism; tested on E. coli infection in mice, which showed reduction of infection compared with control |
| Institute where first reported: | AVIBioPharm. Inc. (Sarepta Therapeutics) |
| Year first mentioned: | 2004 |
| Highest developmental phase: | Preclinical |
| Development status: | Unknown |
| Reason Dropped: | Part of a research program which used the technology in a variety of applications but no further development beyond preclinical seems to have been reported for antibacterial useage |
| External links: | |
| Citation: |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.